Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • AH001
Targeting the TRPV4-RhoA-RhoGDI1 Axis: A Novel Approach for Hypertension Therapy
Posted inCardiology Specialties

Targeting the TRPV4-RhoA-RhoGDI1 Axis: A Novel Approach for Hypertension Therapy

Posted by MedXY By MedXY 09/07/2025
A novel inhibitor AH001 targets the TRPV4-RhoA-RhoGDI1 axis to inactivate RhoA signaling, effectively reducing blood pressure and preventing vascular remodeling in hypertensive models, opening new avenues for antihypertensive drug development.
Read More
  • Elevated MCP1 and FABP4 in Early PCOS Pregnancy: Metabolic Markers Driven by Adiposity Rather Than Disease Status
  • Early Antenatal Prediabetes: A Critical Red Flag for Rapid Postpartum Progression to Type 2 Diabetes
  • Optimizing Anabolic Therapy: A Comparative Analysis of 3-Month vs. 12-Month Romosozumab Regimens in Postmenopausal Osteoporosis
  • Etiology, Management, and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock
  • GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in